AOD 9604 peptide nasal spray is a research-only form of the HGH fragment 176-191. Learn how it works, dosing questions, and safety limits in the U.S.
AOD 9604 peptide nasal spray is an unapproved research product that contains a synthetic fragment of human growth hormone, and vendors market it mainly for fat loss. AOD 9604 is not FDA-approved for human use in the United States, and no published clinical trial has tested an intranasal version of it. That means the spray format is unproven, unregulated, and sold almost entirely on marketing claims rather than data.
What Is AOD 9604?
AOD 9604 (also written AOD-9604) is a 16-amino-acid peptide that matches the tail end of human growth hormone, residues 176 through 191. Scientists modified that fragment to strip out the parts of HGH tied to growth and blood sugar, hoping to isolate its fat-metabolizing effects.
In lab and animal studies, the peptide increased fat breakdown and reduced new fat formation. Human trials in the 2000s reported modest weight loss at injectable doses, and the developer never pursued approval for obesity treatment.
AOD 9604 is not growth hormone. It does not appear to raise IGF-1 or blood glucose the way full HGH can, and that distinction is the main reason it keeps appearing in bodybuilding and biohacking discussions.
Why Do Vendors Sell It as a Nasal Spray?
Injections are the most studied route for AOD 9604, but plenty of people dislike needles. Nasal sprays offer a needle-free option, and sellers often describe them as convenient and better absorbed than oral products.
That pitch runs into a biology problem. Peptides are large, fragile molecules, and the nasal lining is built to keep large molecules out. Absorption depends on molecular size, enzyme breakdown in the nasal mucosa, and whether the formula includes an absorption enhancer — details that are rarely disclosed on a research bottle.
Stability is a second issue. AOD 9604 normally ships as a lyophilized powder because the reconstituted peptide degrades quickly, and a multi-dose spray sitting at room temperature is a far harsher environment than a refrigerated vial. No standard published formulation exists for intranasal AOD 9604, so anyone looking into how to use aod 9604 peptide in this format is working without a reference point.
Nasal Spray vs. Injection vs. Oral Formats
| Format | How it is used | Absorption notes | Human research support |
|---|---|---|---|
| Subcutaneous injection | Injected under the skin | Best-documented route; peptide reaches circulation | Human trials used this route |
| Nasal spray | Sprayed into each nostril | Limited by the nasal lining; enhancers often required; dose accuracy varies | No published human trials |
| Oral capsules and tablets | Swallowed | Digestive enzymes destroy most peptides before absorption | Early oral trials produced mixed, modest results |
| Sublingual drops | Held under the tongue | Absorption is inconsistent and poorly studied | Minimal |
Looking at that table, only the injectable route has real human data behind the doses people discuss online. aod 9604 peptide capsules at least have a small amount of clinical history, while the nasal format has none. Users often assume a spray is gentler and roughly equivalent, but gentler and equivalent are not the same thing.
Dosing Questions and Beginner Confusion
Most online discussion of aod 9604 peptide dose traces back to injectable protocols from research settings, where 250 to 500 mcg per day was common, sometimes split into two administrations. Those numbers come from injection studies, and they do not transfer to a spray bottle.
For a nasal spray, there is no validated conversion. Intranasal bioavailability for peptides this size is generally a small fraction of injected bioavailability, and without knowing the concentration per spray, the enhancer used, or the droplet size, any number is a guess. On the question of aod 9604 peptide dosage for beginners, the accurate answer is that no reliable beginner protocol exists for the intranasal form.
Timing gets similar treatment. Injectable protocols often place AOD 9604 in a fasted state, before morning cardio or at night, based on the theory that fat oxidation is higher then. The reasoning is plausible but unproven, and no study has compared nasal spray timing against any outcome.
Safety, Sides, and Legal Status
AOD 9604 is not approved by the FDA for human use in the United States. It is sold as a research chemical with a not-for-human-consumption label, which means no pharmacy-grade quality control, no verified purity, and no dosing oversight.
Reported side effects in trials were generally mild and included headache, nausea, and injection-site irritation. Those reports come from supervised studies using pharmaceutical-grade material, and they say nothing about a spray made by an unregulated vendor with unknown concentration and unknown preservatives.
The nasal route adds its own concerns. Repeated intranasal use can irritate or damage the nasal lining, and sterility matters because the nose connects directly to the sinuses and airways. Separately, early laboratory work explored whether the HGH fragment could support cartilage repair, but that research is preliminary and does not establish a proven joint treatment.
What to Check Before Buying
Research chemical vendors vary enormously in quality. If you are searching to buy aod-9604 peptide, look for lot-specific third-party certificates of analysis, verified purity figures, and cold-chain shipping. A seller who cannot produce a recent COA for the exact batch is not a reliable source.
Price is a poor quality signal. Cheap AOD 9604 is frequently underdosed or mislabeled, and because no regulator inspects these products, the buyer absorbs nearly all of the risk.
It also helps to keep expectations grounded. Even in the best-designed human trials, AOD 9604 produced modest weight loss, and diet quality plus resistance training accounted for far more of the result than any peptide did.
Bottom Line
AOD 9604 peptide nasal spray is an unapproved, untested delivery format for a peptide whose human data comes from injections and oral tablets. There is no published evidence that intranasal AOD 9604 absorbs well enough to produce a meaningful effect, and no standard dose exists.
Anyone weighing it should account for the unknowns honestly: unverified concentration, no safety data for the intranasal route, and no FDA approval. A healthcare professional can help you review evidence-based options before you spend money on an unproven spray.
Frequently Asked Questions
Is AOD 9604 peptide nasal spray safe?
There is no human safety data for intranasal AOD 9604, and the peptide is not FDA-approved for human use. Nasal sprays from research vendors can vary in concentration, purity, and preservative content, and repeated intranasal use can irritate the nasal lining. Talk to a healthcare professional before using any unapproved peptide.
Does AOD 9604 nasal spray actually work for weight loss?
No published study has tested AOD 9604 as a nasal spray, so its effectiveness by that route is unknown. Injectable AOD 9604 produced only modest weight loss in human trials, and intranasal absorption for peptides of this size is typically much lower than injection. Diet and exercise remain the factors with the strongest evidence behind them.
How much AOD 9604 nasal spray should I take?
No standard nasal spray dose exists. Research protocols using injections often used 250 to 500 mcg per day, but that figure cannot be converted to sprays without knowing the concentration per spray and the absorption enhancer used. Because intranasal bioavailability is unmeasured for AOD 9604, any spray dose circulating online is an estimate rather than a validated protocol.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.